Davis Polk advised Royalty Pharma plc on the deal. Royalty Pharma plc completed its Rule 144A/Regulation S offering of $1 billion aggregate principal amount of its…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
